Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

Andrew T. Reid; Punnam Chander Veerati; Reinoud Gosens; Nathan W. Bartlett; Peter A. Wark; Chris L. Grainge; Stephen M. Stick; Anthony Kicic; Fatemeh Moheimani; Philip M. Hansbro; Darryl A. Knight

doi:10.1016/j.pharmthera.2017.12.009

Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

Andrew T. Reid, Punnam Chander Veerati, Reinoud Gosens, Nathan W. Bartlett, Peter A. Wark, Chris L. Grainge, Stephen M. Stick, Anthony Kicic, Fatemeh Moheimani, Philip M. Hansbro, Darryl A. Knight

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Abstract

Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology.

Original language	English
Pages (from-to)	155-169
Number of pages	15
Journal	Pharmacology and Therapeutics
Volume	185
DOIs	https://doi.org/10.1016/j.pharmthera.2017.12.009
Publication status	Published - 1 May 2018

Access to Document

10.1016/j.pharmthera.2017.12.009

Cite this

@article{709cd96d863148c0b6b65339a5521b51,

title = "Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches",

abstract = "Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology.",

author = "Reid, {Andrew T.} and Veerati, {Punnam Chander} and Reinoud Gosens and Bartlett, {Nathan W.} and Wark, {Peter A.} and Grainge, {Chris L.} and Stick, {Stephen M.} and Anthony Kicic and Fatemeh Moheimani and Hansbro, {Philip M.} and Knight, {Darryl A.}",

year = "2018",

month = may,

day = "1",

doi = "10.1016/j.pharmthera.2017.12.009",

language = "English",

volume = "185",

pages = "155--169",

journal = "Pharmacology and Therapeutics",

issn = "0163-7258",

publisher = "Elsevier",

}

TY - JOUR

T1 - Persistent induction of goblet cell differentiation in the airways

T2 - Therapeutic approaches

AU - Reid, Andrew T.

AU - Veerati, Punnam Chander

AU - Gosens, Reinoud

AU - Bartlett, Nathan W.

AU - Wark, Peter A.

AU - Grainge, Chris L.

AU - Stick, Stephen M.

AU - Kicic, Anthony

AU - Moheimani, Fatemeh

AU - Hansbro, Philip M.

AU - Knight, Darryl A.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology.

AB - Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology.

UR - http://www.scopus.com/inward/record.url?scp=85039860053&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2017.12.009

DO - 10.1016/j.pharmthera.2017.12.009

M3 - Review article

AN - SCOPUS:85039860053

SN - 0163-7258

VL - 185

SP - 155

EP - 169

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

ER -

Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

Abstract

Access to Document

Other files and links

Fingerprint

Cite this